Donor transmitted anaplastic carcinoma in a kidney-transplant recipient

Transplant International

Volumn 18, Issue 9, 2005, Pages 1109-1112

  Krapp, Jan D ^a,b   Brauer, Robert B ^a   Matevossian, Eduard ^a   Gerauer, Klaus E ^a   Thorban, Stefan ^a   Becker, Karin ^a   Stangl, Manfred J ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anaplastic carcinoma; Kidney transplantation; Tumor transmission

Indexed keywords

CISPLATIN; CREATININE; CYCLOSPORIN; CYTOKERATIN 19 FRAGMENT; GAMMA INTERFERON; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAVELBINE; PREDNISOLONE;

ADULT; ANAPLASTIC CARCINOMA; ARTICLE; AUTOPSY; BRAIN BIOPSY; BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RISK; CASE REPORT; CREATININE BLOOD LEVEL; DISEASE TRANSMISSION; GRAFT RECIPIENT; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY CARCINOMA; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LUNG CARCINOMA; LYMPH NODE METASTASIS; MALE; NEPHRECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN DONOR; PRIORITY JOURNAL; TUMOR CELL; CARCINOMA; DONOR; KIDNEY TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY;

BRAIN NEOPLASMS; CARCINOMA; HUMANS; IMMUNOSUPPRESSION; KIDNEY NEOPLASMS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TISSUE DONORS;

EID: 26944477482     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2005.00178.x     Document Type: Article

References (11)

1. Birkeland SA, Storm HH. Risk for tumor and other disease transmission by transplantation: a population-based study of unrecognized malignancies and other diseases in organ donors. Transplantation 2002; 74: 1409.
2. Kauffman HM, McBride MA, Delmonico FL. First report of the United Network for Organ Sharing Transplant Tumor Registry: donors with a history of cancer. Transplantation 2000; 70: 1747.
3. Kauffman HM, McBride MA, Cherikh WS, Spain PC, Marks WH, Roza AM. Transplant tumor registry: donor related malignancies. Transplantation 2002; 74: 358.
4. Loh E, Couch FJ, Hendricksen C, et al. Development of donor-derived prostate cancer in a recipient following orthotopic heart transplantation. JAMA 1997; 277: 133.
5. Mihalov ML, Gattuso P, Abraham K, Holmes EW, Reddy V. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center. Clin Transplant 1996; 10: 248.
6. Sheil AG. Donor-derived malignancy in organ transplant recipients. Transplant Proc 2001; 33: 1827.
7. Stephens JK, Everson GT, Elliott CL, et al. Fatal transfer of malignant melanoma from multiorgan donor to four allograft recipients. Transplantation 2000; 70: 232.
8. Wilson RE, Hager EB, Hampers CL, Corson JM, Merrill JP, Murray JE. Immunologic rejection of human cancer transplanted with a renal allograft. N Engl J Med 1968; 278: 479.
9. Frank S, Muller J, Bonk C, Haroske G, Schackert HK, Schackert G. Transmission of glioblastoma multiforme through liver transplantation. Lancet 1998; 352: 31.
10. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128.
11. Bechstein WO, Dette K, Golling M, Wullstein C. [Development of primary malignancies after liver and kidney transplantation and the treatment approach]. Kongressbd Dtsch Ges Chir Kongr 2002; 119: 398.